key: cord-0743679-l0tg341s
authors: Obi, Koyenum; Baldawi, Harith; Garba, Shamaki; Amoran, Olayiwola; Jenkins, Chris; Gillies, Connor; Penfold, Dana; Dengle, Sunny; Alocozy, Lamar; Falloon, Austin; Bob-Manuel, Tamunoinemi
title: Structural Heart Interventions During COVID-19
date: 2021-07-24
journal: Curr Probl Cardiol
DOI: 10.1016/j.cpcardiol.2021.100934
sha: 5f7a4cbf9d4f8cd50f91d728e86e5dbaea21015a
doc_id: 743679
cord_uid: l0tg341s

The spread of Coronavirus Disease 2019 (COVID-19) pandemic across the globe and the United States presented unprecedented challenges with dawn of new policies to reserve resources and protect the public. One of the major policies adopted by hospitals across the nations were postponement of non-emergent procedures such as transaortic valve replacement (TAVR), left atrial appendage closure device (LAAC), MitraClip and CardioMEMS. Guidelines were based mainly on the avoidable clinical outcomes occurring during COVID-19 era. As our understanding of the SARS-CoV-2 evolved, advanced cardiac procedures may safely continue through careful advanced coordination. We aim to highlight the new guidelines published by different major cardiovascular societies, and discuss solutions to safely perform procedures to improve outcomes in a patient population with high acuity of illness during the COVID-19 pandemic era.

On January 21, 2020, the Centers for Disease Control and Prevention (CDC) confirmed the first case of Coronavirus Disease 2019 in the United States, and by March 11, 2020, the World Health Organization (WHO) had declared the outbreak a global pandemic. As the pandemic continues to rage around the world, the US alone has thus far recorded 33, 257, 768 confirmed cases and 597,727 deaths due to COVID-19, the disease caused by the SARS-CoV-2 virus reflecting the severity of the virus. 1 Based on these figures, the case-fatality rate currently lies at 1.8%, however this percentage is likely to fluctuate as disease prevalence and death rate change over time. 2 The spread of SARS-CoV-2 is known to be facilitated by close person-to-person contact, and exposure to respiratory droplets is recognized as the predominant route of transmission. [3] [4] [5] Evidence also suggests that airborne spread of viral particles is a possible, albeit infrequent, mode of SARS-CoV-2 transmission. [3] [4] [5] [6] In response to uncertainties about COVID-19 severity, transmissibility, and appropriate infection control at the onset of the pandemic, non-emergent medical treatments in the US were temporarily delayed to limit further transmission.

The postponement of non-emergent procedures has impacted an already frail population of patients with structural heart diseases and multiple comorbidities that prevented beneficial procedures such as transaortic valve replacement (TAVR), left atrial appendage closure device (LAAC), MitraClip and CardioMEMS. Studies have demonstrated that TAVR improves healthrelated quality of life in high surgical risk patients with severe aortic stenosis. 43 MitraClip decreases heart failure hospitalization and mortality in patients with symptomatic heart failure with grade 3-4+ mitral regurgitation (MR). 39 CardioMEMS lowers rates of heart failure hospitalization and all cause hospitalizations 44 , while the LAAC device decreases risk of stroke in patients with non-valvular atrial fibrillation. 45 The diversion of resources in response to the pandemic resulted in unavailability of ICU beds, personal protective equipment, and reassignment of hospital staff, which hindered the execution of these structural heart interventions. The overall landscape of the Covid-19 pandemic has led to the publication of a variety of recommended guidelines by several cardiology societies and groups regarding the prioritization of structural heart interventions. Specifically, patients deemed to be high risk for clinical deterioration have been prioritized, while other less urgent cases have been postponed. [9] [10] [11] In our paper, we summarize the outcomes of structural heart procedures in the COVID-19 pandemic era, and proffer solutions to safely reinstitute these procedures without overwhelming the limited available resources. We also aim to highlight the patient population with high acuity of illness who should receive these non-emergent procedures to improve clinical outcomes during a pandemic.

Aortic stenosis is a slowly progressing disease which remains largely silent. It rapidly advances after the onset of symptoms and significantly increases the risk of sudden cardiac death. With a prevalence that varies from 0.2% between ages 50 to 59 years and up to 10% by the 8th decade, it remains a leading cause of cardiovascular mortality in the elderly population. 21 Although the most common clinical presentation includes heart failure, syncope and angina, elderly patients may present with decreased exercise tolerance and gastrointestinal bleeding due to platelet dysfunction or arteriovenous malformation. The onset of symptoms, however small, constitute clinically significant stenosis and a prompt need for intervention. Untreated symptomatic aortic stenosis is estimated to have a two-year mortality rate of 50% to 68% with most patients dying from congestive heart failure. 22 Since its approval in 2011, TAVR has gradually become the standard of care for symptomatic patients with severe aortic stenosis who are intermediate or high surgical risk. In 2019, the FDA expanded its approval to include low surgical risk patients citing TAVR as less invasive as it involves smaller incisions and has a shorter recovery time when compared to open heart surgery. 23 COVID-19 pandemic has placed an enormous burden on the healthcare system in the United States and around the world. Hospital systems implemented large scale changes to accommodate for a surge in the number of cases with significant implications on wait times for patients with structural heart disease who are also at high risk due to their age and comorbidities. In one small study of 77 patients whose TAVR was deferred due COVID-19 pandemic, up to 10% of patients experienced a cardiac event within the first month and up to 35% of patients did so over the next three months. 26 Longer wait times for patients awaiting TAVR has been linked with increasing mortality and heart failure hospitalization. 27 This may be further exacerbated since the COVID-19 case fatality rate is highest amongst elderly patients with preexisting cardiac condition. 28 Malasaire et al also observed that the probability of death in patients with severe aortic stenosis without TAVR intervention at 1, 3, 6, 12, and 24 months were of 3.8%, 10.4%, 23.3%, 27.5%, and 41.1% mortality, respectively, whereas a 30-day allcause mortality rate for TAVR was postulated at 2.2%. 7, 8 Although the risk of hospital exposure to COVID 19 is still unknown, the risk of delaying the procedure should be balanced against the risk of contracting COVID-19 infection both before and after the procedure. Emerging evidence support similar outcomes of structural heart interventions performed before or during the era of COVID-19. A retrospective study at a single, tertiary care hospital in Israel compared TAVR outcomes between 59 patients during the COVID-19 era and 198 patients before the COVID-19 era. 31 The primary outcome revealed similar TAVR device success according to the Valve Academic Research Consoritum 2 (VARC-2) criteria (97% vs 93%, p = 0.53). 31 Additionally, there were no documented cases of COVID-19 at follow up. Additionally, a series of 6 cases of patients undergoing TAVR with a same-day discharge protocol during the COVID-19 pandemic was described by Rai, et al. 41 Patients were discharged with remote cardiac monitoring and had follow up via telemedicine within 2 days, 2 weeks, and 30 days, revealing no post-procedural complications and significant symptomatic resolution. A case series of transcatheter mitral valve repair with clip in 2 patients with severe MR and cardiogenic shock during the COVID-19 era was outlined by Chitturi, et al. 42 Both patients underwent successful procedure, had mild residual MR confirmed with transthoracic echocardiography, and reported significant functional improvement (NYHA Class I and II) at one-month follow up. One patient demonstrated evidence of an atrial septal defect intraoperatively requiring transcatheter closure with a septal occluder device. 42

There are various recommendations currently guiding clinicians in optimizing care to this patient population. The goals of each group center surround protecting patients and staff from unnecessary exposure to SARS-CoV-19, as well as preserving the already constrained health care resources.

The ACC and SCAI released a position statement recognizing increased mortality risk associated with delays in some structural cardiac intervention. 10 29 These patients were to be followed up weekly by the procedural team and managed with GDMT. Understandably, mitral valve repair with the MitraClip demonstrates increased risk of particular aerosolization due to requirement of TransEsophageal Echo (TEE) and ventilator use. 13 These changes in guidelines reflects a serious concern for patients with asymptomatic degenerative chronic MR. Prior studies have demonstrated better postoperative prognosis and survival rates when LV EF remains > 60% 36 , LVESD > 40%, and absence of new atrial fibrillation or pulmonary hypertension. [33] [34] [35] When patients progress to symptomatic severe MR (NYHA class III or IV preoperative), regardless of preserved left ventricular function, they have a worse postoperative prognosis. 37 It is also important to note an increase in sudden death when patients progress to symptomatic degenerative chronic MR. 38 By delaying repair, these patients are at risk for irreversible cardiac deterioration or sudden cardiac death.

Atrial Fibrillation is a condition that has continued to show increasing prevalence in our population over recent decades, whether due to improving diagnostic and preventative measures or purely due to higher incidence with our increasingly aging population. 14 Some estimates predict atrial fibrillation has a prevalence in as high as 2% of the population and as high as 13% in the elderly population, including those over 80. 14, 15 This increasing incidence of atrial fibrillation has correlations with also-increasing use of oral anticoagulation for stroke prevention. These large numbers of patients with atrial fibrillation, however, also bring contraindications to oral anticoagulation. Sources vary based on inclusion criteria for contraindications to taking oral anticoagulation, but the presence of contraindications have been reported in anywhere from 13% to 18% of patients. Prior bleeding-whether gastrointestinal or intracranial in source-accounted for about one-third of these contraindications, according to the ORBIT-AF Registry. 16 When contraindications to oral anticoagulation are present, the question posits itself: does the benefit of anticoagulation for stroke prevention but including the risk of bleeding outweigh the risk of foregoing anticoagulation to face the higher risk of stroke?

Left atrial appendage closure with a WATCHMAN device showed non-inferiority to warfarin therapy in stroke prevention, which provides a legitimate option for patients with atrial fibrillation and contraindications to oral anticoagulation. 17 While pooled meta-analysis of the PREVAIL and PROTECT-AF trials at 5 years showed similar mortality and stroke prevention between groups, there was a benefit of a 1.7% rate of major bleeding in the left atrial appendage closure group versus 3.6% in the group receiving warfarin. 18 The ability to quickly schedule and complete now routine procedures such as a left atrial appendage closure, however, became strained during the COVID-19 pandemic in 2020. The ACC and SCAI released reviews for structural heart disease practice in 2020 assessing and giving guidelines for triaging patients requiring valve

replacements, but there is a lack of data on delays in Watchman device placement for atrial fibrillation during the pandemic. 12, 29 These statements give guidelines on stratifying into tiers for how severe the valvular disorders are, which would be congruent with stratifying atrial fibrillation patients based on their CHA2DS2-VASc scoring. A CHA2DS2-VASc score of 5, for instance, correlates to a 10% risk of stroke, TIA, or systemic embolism over the course of a year. 19 Hence, extrapolation of Friberg's data leads us to expect that a 6-month delay in WATCHMAN device placement will on average lead to 5 thromboembolic events out of every 100 patients with contraindications to oral anticoagulation. One recently released retrospective study assessed same day discharge versus non-same day discharge after WATCHMAN device implantation, and found no statistically significant difference in post-operative mortality or other complications evaluated. 20 These findings, along with the ACC recommendations for catheterization lab adaptations during the COVID-19 pandemic lead us to think that with appropriate stratification, WATCHMAN device placement is still feasible and likely still warranted during times of environmental and resource constraints. 12 The exact CHA2DS2-VASc scores needed to place WATCHMAN candidates into a tier system has not been decided upon at this point, but with increasing scores, clinicians should weigh heavily on a case-by-case basis whether the procedure is indicated in a setting proven to be safe for patients even during the COVID-19 pandemic. Further studies looking at triaging of these procedures during the pandemic will be beneficial in the future when similar situations of limited resources overwhelm our healthcare system.

The decision to proceed with a structural heart procedure during the COVID-19 pandemic presents unprecedented challenges. However, delivering advanced cardiac care to patients can continue in a safe manner through care coordination and thorough planning. The guidelines for postponing elective procedures is based on the likelihood of significant, avoidable clinical outcomes occurring acutely in the postponement period. In the future, we hope to shed light on the ambiguity surrounding structural heart procedures such as TAVR, Mitraclip, Watchman, and CardioMEMS during a pandemic by performing a retrospective analysis of procedural outcomes at our institution. 

Principles of epidemiology: home|self-study course ss1978|cdc

Transmission of sars-cov-2: a review of viral, host, and environmental factors

Covid-19 outbreak associated with air conditioning in restaurant, guangzhou, china

Particle sizes of infectious aerosols: implications for infection control. The Lancet Respiratory Medicine

Mortality while waiting for aortic valve replacement. The Annals of Thoracic Surgery

Comments on evaluating out-of-hospital 30-day mortality after transfemoral transcatheter aortic valve replacement

Precautions and procedures for coronary and structural cardiac interventions during the covid-19 pandemic: guidance from canadian association of interventional cardiology

Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: An ACC/SCAI position statement

Restructuring structural heart disease practice during the covid-19 pandemic

Guidelines for balancing priorities in structural heart disease during the covid-19 pandemic

Burden of atrial fibrillationassociated ischemic stroke in the united states

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (Atria) Study

Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (Orbit-af) registry

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study

Safety and feasibility of same-day discharge after left atrial appendage closure with the watchman device

Aortic stenosis: pathophysiology, diagnosis, and therapy

Aortic stenosis: diagnosis and treatment

FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery

5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial

Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery

Characteristics and outcomes of patients deferred for transcatheter aortic valve replacement because of covid-19

Temporal trends and clinical consequences of wait times for transcatheter aortic valve replacement: a population-based study

The science underlying covid-19: implications for the cardiovascular system

Triage considerations for patients referred for structural heart disease intervention during the covid-19 pandemic

Transcatheter aortic valve replacement during the COVID-19 pandemic-A Dutch single-center analysis

Transcatheter aortic valve implantation during the covid-19 pandemic

Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: results of an instrumental variable analysis

Mitral valve surgery: wait and see vs. early operation

Changes in left ventricular volume and decline in ejection fraction after degenerative mitral valve repair: The math makes sense. The Journal of Thoracic and Cardiovascular Surgery

Timing of valve repair for severe degenerative mitral regurgitation and long-term left ventricular function

Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation

Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study

Sudden death in mitral regurgitation due to flail leaflet

Transcatheter mitral-valve repair in patients with heart failure

Management of structural heart disease and acute coronary syndromes in the covid-19 pandemic

Transcatheter aortic valve replacement same-day discharge for selected patients: a case series

Transcatheter mitral valve repair with mitraclip for severe mitral regurgitation and cardiogenic shock during the covid-19 pandemic

Beyond adding years to life: health-related quality-of-life and functional outcomes in patients with severe aortic valve stenosis at high surgical risk undergoing transcatheter aortic valve replacement

Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study

Clinical Outcomes of Mortality, Readmissions, and Ischemic Stroke Among Medicare Patients Undergoing Left Atrial Appendage Closure via Implanted Device